WLWT: UC hosts RESET epilepsy trial

WLWT recently highlighted the RESET study, a trial at the University of Cincinnati that will study a new treatment for the most severe and deadly form of epilepsy.

Brandon Foreman, MD, site principal investigator at UC for the trial being conducted across approximately 50 hospital emergency departments across the country, told WLWT the study focuses on a condition called status epilepticus (SE).

"About 10 percent of the folks who have seizures, when they come into the emergency department, are having status epilepticus," said Foreman, associate professor and associate director of neurocritical care research in the Department of Neurology and Rehabilitation Medicine in UC’s College of Medicine and a UC Health physician. SE is a disorder Foreman described as "seizures that don't stop." 

The trial will test a new drug, ganaxolone, a neurosteroid your brain produces that can help stop seizures that won't end on their own.

"So, the promise with this medication is if you're still having seizures, despite that kind of class, one level of evidence medication...that we can give this medication and it sort of fits in at that point. Hopefully, we'll stop the seizures," Foreman said.

Watch the WLWT story.

Read more about the research.

Featured photo at top of ambulance. Photo/Camilo Jimenez/Unsplash.

Related Stories

1

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.